title: Multimodality treatment of noninflammatory stage IIIb breast cancer.
abstract: OBJECTIVE
  The 1990s have established the contribution of multimodality therapy in the management of IIIb noninflammatory breast cancer (IIIb NIBC), by reducing the odds of recurrence and death.
  
  
  METHODS
  A total of 300 women with IIIb NIBC received a multimodality therapy. The treatment consisted of neoadjuvant chemotherapy [FAC (5-fluorouracil, Adriamycin, cyclophosphamide) regimen], radical (Halsted) mastectomy or modified (Patey mastectomy), postoperative radiotherapy, and adjuvant chemohormone therapy [FAC regimen + cyclophosphamide, 5-fluorouracil and methotrexate (CMF) regimen or Tamoxifen].
  
  
  RESULTS
  Complete or partial clinical response (CR or PR) after neoadjuvant chemotherapy was obtained in 83% patients. Ninety-nine patients (33%) survived 5 years without evidence of disease (NED). The uni- and multivariate analyses factors that had significant influence on the treatment results were: clinical response to neoadjuvant chemotherapy, pathological tumor size, and microscopical status of the axillary lymph nodes.
  
  
  CONCLUSIONS
  We conclude that neoadjuvant FAC regimen chemotherapy is very effective in producing objective tumor regression and offers the benefit of radical mastectomy to patients with previously unresectable IIIb NIBC.
authors.affiliation: Department of Radiotherapy, Maria Sklodowska-Curie Memorial Center of Oncology, Cracow, Poland.
authors.forename: B
authors.initials: B
authors.lastname: Gliński
authors.forename: M
authors.initials: M
authors.lastname: Pawlicki
authors.forename: M
authors.initials: M
authors.lastname: Reinfuss
authors.forename: J
authors.initials: J
authors.lastname: Skołyszewski
authors.forename: A
authors.initials: A
authors.lastname: Brandys
authors.forename: K
authors.initials: K
authors.lastname: Krzemieniecki
authors.forename: B
authors.initials: B
authors.lastname: Zuchowska
authors.forename: J
authors.initials: J
authors.lastname: Mitus
authors.forename: A
authors.initials: A
authors.lastname: Stelmach
authors.forename: T
authors.initials: T
authors.lastname: Walasek
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008197:Lymph Node Excision; D015411:Mastectomy, Modified Radical; D015409:Mastectomy, Radical; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D016019:Survival Analysis; D013629:Tamoxifen / Q000008:administration & dosage
chemical_list: D013629:Tamoxifen; D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate